News >

TAS-102 Expands Arsenal in Gastric Cancer, But Long Road Ahead for Research

Brandon Scalea
Published: Friday, May 24, 2019

Mark M. Zalupski, MD

Mark M. Zalupski, MD

Although the recently FDA-approved agent TAS-102 (trifluridine/tipiracil; Lonsurf) has shown modest activity in patients with advanced gastric cancer, this patient population as a whole still represents a significant unmet need, said Mark M. Zalupski, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x